Aneuploidy
Summary
Aneuploidy is the state of having an abnormal number of chromosomes — a karyotype that deviates from the euploid diploid count (46 in humans) by whole-chromosome gains or losses. It is the most common genomic feature of solid cancers and affects a greater proportion of the cancer genome than any other mutation type (Gerstung et al., 2020). Aneuploidy arises through two distinct routes — a single catastrophic missegregation event producing clonal (homogeneous) aneuploidy, or ongoing chromosomal-instability producing subclonal (heterogeneous) aneuploidy — and the distinction carries fundamentally different evolutionary and clinical implications (Turajlic et al., 2019).
Definition
Aneuploidy is a state of abnormal chromosome number. It is distinct from:
- Euploidy — the normal diploid chromosome complement (2n = 46 in humans)
- Polyploidy — whole-genome multiplication (3n, 4n, etc.). whole-genome-duplication produces tetraploidy (4n), which is a form of polyploidy, not aneuploidy — though it creates a permissive background for subsequent aneuploidy
- Segmental aneuploidy — gain or loss of part of a chromosome arm (a copy-number-alteration at the sub-chromosomal scale). The boundary between segmental aneuploidy and focal CNA is a continuum, not a sharp divide
An aneuploid tumor cell may carry trisomy 7 (gain of one copy of chromosome 7, 3 total), monosomy 3 (loss of one copy, 1 total), or complex karyotypes with gains and losses across multiple chromosomes.
Clonal vs. Subclonal Aneuploidy
The distinction between clonal and subclonal aneuploidy is clinically and evolutionarily fundamental (Turajlic et al., 2019):
| Feature | Clonal Aneuploidy | Subclonal Aneuploidy |
|---|---|---|
| Distribution | Present in all (or nearly all) cancer cells | Present in a subset of cancer cells |
| Origin | Single catastrophic event or early selective sweep | Ongoing chromosomal-instability |
| Karyotype | Homogeneous — all cells share the same aneuploidies | Heterogeneous — different cells carry different aneuploidies |
| Evolutionary pattern | Punctuated — early catastrophe, then stasis | Branching or neutral — ongoing diversification |
| Clinical | Fast growth, widespread metastasis, monophyletic seeding | Variable; moderate subclonal aneuploidy worsens prognosis |
Tumors with clonal aneuploidy but no ongoing CIN are homogeneously aneuploid. Tumors with ongoing CIN are heterogeneously (subclonally) aneuploid. The distinction cannot be made from a single biopsy of a single time point — it requires multi-region sequencing or longitudinal sampling to determine whether the aneuploidy pattern is stable (clonal, no CIN) or evolving (subclonal, active CIN).
The Fitness Paradox of Aneuploidy
Aneuploidy has a paradoxical relationship with cellular fitness (chromosomal-instability):
Adaptive benefit. Aneuploidy provides large-effect phenotypic variation. Gaining or losing an entire chromosome alters the dosage of hundreds of genes simultaneously, enabling rapid exploration of the fitness landscape. This is the genetic basis of the hopeful-monster concept in cancer: a single missegregation event can produce a radically altered clone with novel adaptive properties.
Fitness cost. Aneuploidy is intrinsically deleterious at the cellular level. Imbalanced gene dosage disrupts protein complex stoichiometry, increases proteotoxic stress, and triggers the DNA damage response. The deleterious effects scale with the degree of aneuploidy — cells tolerate a few aneuploidies but collapse under many.
This tension produces the “just-right” aneuploidy level observed pan-cancer (Turajlic et al., 2019):
| Aneuploidy burden | Survival | Interpretation |
|---|---|---|
| Low (<25% of genome) | Better | Insufficient diversity for adaptation |
| Moderate (25–75%) | Worse | Adaptive sweet spot — diversity without lethality |
| Excessive (>75%) | Better | Cell-autonomous lethality from proteotoxic and mitotic catastrophe |
The survival advantage at high aneuploidy is not because extreme aneuploidy is beneficial — it is because the tumor cells that carry it die. The improved prognosis reflects the collapse of the tumor’s adaptive capacity, not a triumph of therapy.
Aneuploidy and Metastasis
Aneuploidy is strongly associated with metastatic competence. In TRACERx Renal, metastasis-competent clones were distinguished by the degree of aneuploidy and chromosome complexity, and specific aneuploidies — loss of 9p and loss of 14q — were enriched in metastasizing clones. No evidence of selection for small-scale SNV mutations was found in the metastatic transition, suggesting that the large-effect phenotypic changes produced by aneuploidy are the primary genetic driver of metastatic competence (Turajlic et al., 2019).
Punctuated tumors with high clonal aneuploidy grow fast, metastasize widely, and seed metastases monophyletically — a single founding clone from the primary tumor establishes all metastatic sites. Gradual tumors with lower clonal aneuploidy but ongoing subclonal CNA produce fewer metastases (oligometastases) with greater intermetastatic heterogeneity (Turajlic et al., 2019).
Measurement
Aneuploidy is measured through the same signals as copy-number-alteration:
- logR (read depth ratio): Whole-chromosome gains or losses shift the logR across the entire chromosome
- BAF (B-allele frequency): Whole-chromosome aneuploidy shifts BAF at all heterozygous SNP positions on the chromosome
- Cytogenetics / FISH: Traditional chromosome counting remains the gold standard for clonal aneuploidy but lacks the resolution to detect subclonal aneuploidy at low frequency
The percentage of the genome affected by aneuploidy — the aneuploidy burden — is the metric used in the Turajlic et al. (2019) pan-cancer analysis. It is computed as the fraction of the genome with copy number ≠ 2 (after correcting for purity and ploidy).
Limitations
CIN vs. aneuploidy distinction requires longitudinal data. A tumor classified as clonally aneuploid from a single biopsy may in fact have ongoing CIN that has not yet produced detectable subclonal aneuploidy. Conversely, a tumor with detected subclonal aneuploidy may be in the process of a selective sweep that will eliminate the diversity within a few doublings. Single-timepoint data cannot distinguish these scenarios.
Aneuploidy burden is confounded by WGD. Whole-genome-doubled tumors (tetraploid, 4n) can tolerate more aneuploidy before reaching the lethal threshold because the relative dosage imbalance from gaining or losing one copy is halved (1/4 vs. 1/2). Comparing aneuploidy burden between WGD and non-WGD tumors requires ploidy normalization.
Aneuploidy is not random. Specific chromosomes are gained or lost at different frequencies across cancer types (e.g., 1q gain, 8q gain, 17p loss are recurrent pan-cancer; 9p loss and 14q loss are enriched in ccRCC). The non-random distribution suggests selection shapes the aneuploidy landscape, but distinguishing selection from differential susceptibility to missegregation is methodologically challenging.